规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
靶点 |
Oxytocin ( IC50 = 0.65 nM )
|
---|---|
参考文献 |
分子式 |
C27H34N4O5
|
---|---|
分子量 |
494.58266
|
精确质量 |
494.25
|
元素分析 |
C, 65.57; H, 6.93; N, 11.33; O, 16.17
|
CAS号 |
820957-38-8
|
相关CAS号 |
(S)-Retosiban
|
外观&性状 |
Solid powder
|
SMILES |
CC[C@H](C)[C@@H]1C(=O)N[C@@H](C(=O)N1[C@H](C2=COC(=N2)C)C(=O)N3CCOCC3)C4CC5=CC=CC=C5C4
|
InChi Key |
PLVGDGRBPMVYPB-FDUHJNRSSA-N
|
InChi Code |
InChI=1S/C27H34N4O5/c1-4-16(2)23-25(32)29-22(20-13-18-7-5-6-8-19(18)14-20)26(33)31(23)24(21-15-36-17(3)28-21)27(34)30-9-11-35-12-10-30/h5-8,15-16,20,22-24H,4,9-14H2,1-3H3,(H,29,32)/t16-,22+,23+,24+/m0/s1
|
化学名 |
(3R,6R)-6-[(2S)-butan-2-yl]-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2-methyl-1,3-oxazol-4-yl)-2-morpholin-4-yl-2-oxoethyl]piperazine-2,5-dione
|
别名 |
GSK221,149; GSK 221,149; GSK-221,149; GSK221149; GSK 221149; GSK-221149; Retosiban; GSK221149A; GSK 221149A; GSK-221149A
|
HS Tariff Code |
2934.99.9001
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
DMSO: ~100 mg/mL (~202.2 mM )
|
---|
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 2.0219 mL | 10.1096 mL | 20.2192 mL | |
5 mM | 0.4044 mL | 2.0219 mL | 4.0438 mL | |
10 mM | 0.2022 mL | 1.0110 mL | 2.0219 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT01867996 | Completed | Drug: Retosiban Drug: EFZ 600 mg |
Obstetric Labour, Premature | GlaxoSmithKline | June 11, 2013 | Phase 1 |
NCT02377414 | Completed | Drug: Placebo Drug: Retosiban solution for Infusion |
Obstetric Labour, Premature | GlaxoSmithKline | March 2, 2015 | Phase 1 |
NCT01702376 | Completed | Drug: Retosiban 100 mg Drug: Retosiban 800 mg Drug: Placebo |
Obstetric Labour, Premature | GlaxoSmithKline | October 3, 2012 | Phase 1 |
NCT02292784 | Completed | Drug: Retosiban Drug: Atosiban Drug: Placebo |
Obstetric Labour, Premature | GlaxoSmithKline | June 1, 2015 | Phase 3 |
NCT00404768 | Completed | Drug: GSK221149A Drug: Placebo |
Obstetric Labour, Premature | GlaxoSmithKline | October 12, 2007 | Phase 2 |